 - Monjuvi U.S. net product sales of 14.9 million US 18.0 million, 16 growth Q-Q - MorphoSys announced and subsequently completed its acquisition of Constellation Pharmaceuticals - Announced and closed US 2.0 billion strategic funding partnership with Royalty Pharma - Updated group financial guidance - Conference call and webcast in English tomorrow, July 29, 2021, at 2:00pm CEST 1:00pm BST8:00am EDT PLANEGGMUNICH, GERMANY ACCESSWIRE July 29, 2021 MorphoSys AG FSE:MORNASDAQ:MOR reports financial results for the second quarter and the first half year of 2021. We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum continuing into Q3, said Jean-Paul Kress, M.D. 